Cell Genesys Announces Phase III Results for GVAX

Cell Genesys, Inc. announced results from further analyses of VITAL-1, the Company’s recently terminated Phase 3 clinical trial which compared GVAX immunotherapy for prostate cancer to Taxotere (docetaxel) chemotherapy plus prednisone and enrolled 626 advanced prostate cancer patients with asymptomatic castrate-resistant metastatic disease.
centredaily.com